세계의 동물용 의약품 시장 예측(-2030년)

Market Overview

The veterinary medicine market is projected to register a healthy CAGR of 5.57% by 2030. Developing persistent diseases, expanding paces of pet proprietorship, and expanded meat and the extension of the veterinary medicine industry may be energized by endeavors to advance animal cultivation and an expansion in pet reception are the key market drivers improving the Veterinary Medicine market development.

The market improvement is anticipated to be supported by the rising reception of pet medical coverage to pay for veterinary administrations in different industrialized countries. Sweden, the Unified Realm, and Canada have flourishing pet healthcare coverage markets. There has been a sharp ascent in the boundless utilization of pet healthcare coverage in China. Two huge elements adding to the acknowledgment of pet medical care protection are the developing public comprehension of pet medical problems and the rising ubiquity of pets.

Market Segmentation

The market portions of Veterinary Medicine, considering the course of administration, incorporate oral and parental. The Veterinary Medicine market division, by Animal Type, incorporates Tamed and Sidekick animals.

Based on Product, the market portions of Veterinary Medicine incorporate Medications and Immunizations. In view of the Distribution Channel, the market of the veterinary medicine division incorporates Veterinary Medical clinics and Centers, Retail locations, and Online Drug stores.

Regional Analysis

The North American Veterinary Medicine market represented USD 12.48 billion in 2021 and is supposed to display a huge CAGR development during the review time frame.

The Asia Pacific Veterinary Medicine market is expected to increment considerably during the period. Market extension in this space has been helped by expanded friend creature reception and rising creature wellbeing concerns. The Asia Pacific region's market is likewise expected to be driven by rising veterinary and creature medical care costs and a sizable cow populace. Besides, the China market of veterinary medicine held the biggest market share, and the Indian market of veterinary medicine was the quickest developing market in the Asia-Pacific region.

Because of the inescapable presence of huge industry players and the Region's advanced medical care framework, Europe is expected to rule the market of veterinary medicine over the projection period. Moreover, strong unofficial laws and extending measures to advance creature well-being will additionally speed up this Region's market improvement rate.

Significant market organizations are putting critical cash in Research and development to extend their item contributions, which will fuel further market development in Veterinary Medicine. With huge industry changes, including new item deliveries, legally binding arrangements, consolidations, and acquisitions, expanded speculations, and cooperation with different associations, market members are likewise attempted different vital exercises to extend their presence.

Producing locally to reduce functional expenses is one of the primary business strategies utilized by the Veterinary Medicine industry to serve clients and increment the market area. The Veterinary Medicine industry has as of late given medicine the absolute most significant benefits.

Major Players

Key Companies in the Veterinary Medicine market are Ceva, Boehringer Ingelheim, Dechra Pharmaceuticals plc, Bayer AG, Chanelle Pharma Group, Elanco, Norbrook Laboratories, Merck Animal Health, Vetiqyubik S.A., and Zoetis.

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

• 2.1 SCOPE OF THE STUDY 15
• 2.2 RESEARCH OBJECTIVE 15
• 2.3 MARKET STRUCTURE 15
• 2.4 ASSUMPTIONS & LIMITATIONS 16

3 RESEARCH METHODOLOGY

• 3.1 DATA MINING 17
• 3.2 SECONDARY RESEARCH 18
• 3.3 PRIMARY RESEARCH 19
• 3.4 BREAKDOWN OF PRIMARY RESPONDENTS 20
• 3.5 FORECASTING TECHNIQUES 20
• 3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 22
  • 3.6.1 BOTTOM-UP APPROACH 23
  • 3.6.2 TOP-DOWN APPROACH 23
• 3.7 DATA TRIANGULATION 24
• 3.8 VALIDATION 24

4 MARKET DYNAMICS

• 4.1 OVERVIEW 25
• 4.2 DRIVERS 26
  • 4.2.1 GROWING RATES OF PET OWNERSHIP 26
  • 4.2.2 RISING ZOONOTIC & CHRONIC DISEASES ANIMALS 26
  • 4.2.3 INCREASING MEAT CONSUMPTION ATTRACTING MANDATORY VACCINATION 26
• 4.3 RESTRAINT 27
  • 4.3.1 SHORTAGE OF VETERINARIANS 27
  • 4.3.2 STRINGENT REGULATORY GUIDELINES PERTAINING TO VACCINES APPROVAL FOR ANIMALS 27
• 4.4 OPPORTUNITY 28
  • 4.4.1 INCREASING INVESTMENT IN VETERINARY HOSPITALS 28

5 MARKET FACTOR ANALYSIS

• 5.1 VALUE CHAIN ANALYSIS 29
  • 5.1.1 R&D 30
  • 5.1.2 MANUFACTURING 30
  • 5.1.3 DISTRIBUTION & SALES 30
  • 5.1.4 POST-SALES REVIEW/MONITORING 30
• 5.2 PORTER'S FIVE FORCES MODEL 31
  • 5.2.1 THREAT OF NEW ENTRANTS 31
  • 5.2.2 BARGAINING POWER OF SUPPLIERS 32
  • 5.2.3 THREAT OF SUBSTITUTES 32
  • 5.2.4 BARGAINING POWER OF BUYERS 32
  • 5.2.5 INTENSITY OF RIVALRY 32
• 5.3 IMPACT OF COVID-19 32
  • 5.3.1 OVERVIEW 32
  • 5.3.2 IMPACT ON MEAT CONSUMPTION 33
  • 5.3.3 IMPACT ON VETERINARY MEDICINE MARKET 33

6 GLOBAL VETERINARY MEDICINE MARKET, BY ANIMAL TYPE

• 6.1 OVERVIEW 34
• 6.2 DOMESTICATED 35
• 6.3 COMPANION 35

7 GLOBAL VETERINARY MEDICINE MARKET, BY PRODUCT

• 7.1 OVERVIEW 37
• 7.2 DRUG 38
• 7.3 VACCINES 39

8 GLOBAL VETERINARY MEDICINE MARKET, BY ROUTE OF ADMINISTRATION

• 8.1 OVERVIEW 40
• 8.2 ORAL 41
• 8.3 PARENTERAL 41
• 8.4 OTHERS 42

9 GLOBAL VETERINARY MEDICINE MARKET, BY DISTRIBUTION CHANNEL

• 9.1 OVERVIEW 43
• 9.2 VETERINARY HOSPITALS & CLINICS 44
• 9.3 RETAIL STORES 44
• 9.4 ONLINE PHARMACIES 45

10 GLOBAL VETERINARY MEDICINE MARKET, BY REGION

• 10.1 OVERVIEW 46
• 10.2 AMERICAS 48
  • 10.2.1 NORTH AMERICA 50
    • 10.2.1.1 US 52
    • 10.2.1.2 CANADA 53
  • 10.2.2 LATIN AMERICA 54
• 10.3 EUROPE 56
  • 10.3.1 WESTERN EUROPE 58
    • 10.3.1.1 GERMANY 60
    • 10.3.1.2 UK 61
    • 10.3.1.3 FRANCE 62
    • 10.3.1.4 ITALY 63
    • 10.3.1.5 SPAIN 64
    • 10.3.1.6 REST OF WESTERN EUROPE 65
  • 10.3.2 EASTERN EUROPE 67
• 10.4 ASIA-PACIFIC 69
  • 10.4.1 CHINA 71
  • 10.4.2 JAPAN 72
  • 10.4.3 INDIA 73
  • 10.4.4 AUSTRALIA 74
  • 10.4.5 SOUTH KOREA 75
  • 10.4.6 REST OF ASIA-PACIFIC 76
• 10.5 MIDDLE EAST & AFRICA 78
  • 10.5.1 SAUDI ARABIA 80
  • 10.5.2 UNITED ARAB EMIRATES 81
  • 10.5.3 OMAN 83
  • 10.5.4 KUWAIT 84
  • 10.5.5 QATAR 85
  • 10.5.6 REST OF THE MIDDLE EAST & AFRICA 86

11 COMPETITIVE LANDSCAPE

• 11.1 OVERVIEW 88
• 11.2 COMPETITIVE BENCHMARKING 89
• 11.3 GLOBAL VETERINARY MEDICINE MARKET: COMPANY RANKING 90
• 11.4 LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS 91
• 11.5 MAJOR GROWTH STRATEGY IN THE GLOBAL VETERINARY MEDICINE MARKET 91
• 11.6 KEY DEVELOPMENTS & GROWTH STRATEGIES 92
  • 11.6.1 NEW PRODUCT LAUNCHES 92
  • 11.6.2 PARTNERSHIPS/AGREEMENTS 92
  • 11.6.3 EXPANSIONS 93
  • 11.6.4 ACQUISITIONS 93
• 11.7 FINANCIAL MATRIX 94

12 COMPANY PROFILES

• 12.1 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 96
  • 12.1.1 COMPANY OVERVIEW 96
  • 12.1.2 FINANCIAL OVERVIEW 97
  • 12.1.3 PRODUCTS/SERVICES OFFERED 97
  • 12.1.4 KEY DEVELOPMENTS 99
  • 12.1.5 SWOT ANALYSIS 99
  • 12.1.6 KEY STRATEGIES 100
• 12.2 CEVA 101
  • 12.2.1 COMPANY OVERVIEW 101
  • 12.2.2 FINANCIAL OVERVIEW 101
  • 12.2.3 PRODUCTS/SERVICES OFFERED 102
  • 12.2.4 KEY DEVELOPMENTS 102
  • 12.2.5 SWOT ANALYSIS 103
  • 12.2.6 KEY STRATEGIES 103
• 12.3 ZOETIS 104
  • 12.3.1 COMPANY OVERVIEW 104
  • 12.3.2 FINANCIAL OVERVIEW 104
  • 12.3.3 PRODUCTS/SERVICES OFFERED 105
  • 12.3.4 KEY DEVELOPMENTS 107
  • 12.3.5 SWOT ANALYSIS 107
  • 12.3.6 KEY STRATEGIES 107
• 12.4 MERCK ANIMAL HEALTH 108
  • 12.4.1 COMPANY OVERVIEW 108
  • 12.4.2 FINANCIAL OVERVIEW 109
  • 12.4.3 PRODUCTS/SERVICES OFFERED 110
  • 12.4.4 KEY DEVELOPMENTS 111
  • 12.4.5 SWOT ANALYSIS 112
  • 12.4.6 KEY STRATEGIES 112
• 12.5 CHANELLE PHARMA GROUP 113
  • 12.5.1 COMPANY OVERVIEW 113
  • 12.5.2 FINANCIAL OVERVIEW 113
  • 12.5.3 PRODUCTS/SERVICES OFFERED 113
  • 12.5.4 KEY DEVELOPMENTS 115
  • 12.5.5 SWOT ANALYSIS 115
  • 12.5.6 KEY STRATEGIES 115
• 12.6 ELANCO 116
  • 12.6.1 COMPANY OVERVIEW 116
  • 12.6.2 FINANCIAL OVERVIEW 117
  • 12.6.3 PRODUCTS/SERVICES OFFERED 118
  • 12.6.4 KEY DEVELOPMENTS 119
  • 12.6.5 SWOT ANALYSIS 120
  • 12.6.6 KEY STRATEGIES 120
• 12.7 DECHRA PHARMACEUTICALS PLC 121
  • 12.7.1 COMPANY OVERVIEW 121
  • 12.7.2 FINANCIAL OVERVIEW 121
  • 12.7.3 PRODUCTS/SERVICES OFFERED 122
  • 12.7.4 KEY DEVELOPMENTS 123
  • 12.7.5 SWOT ANALYSIS 123
  • 12.7.6 KEY STRATEGIES 123
• 12.8 BAYER AG 124
  • 12.8.1 COMPANY OVERVIEW 124
  • 12.8.2 FINANCIAL OVERVIEW 124
  • 12.8.3 PRODUCTS/SERVICES OFFERED 125
  • 12.8.4 KEY DEVELOPMENTS 126
  • 12.8.5 SWOT ANALYSIS 127
  • 12.8.6 KEY STRATEGIES 127
• 12.9 VETOQUINOL SA. 128
  • 12.9.1 COMPANY OVERVIEW 128
  • 12.9.2 FINANCIAL OVERVIEW 128
  • 12.9.3 PRODUCTS/SERVICES OFFERED 129
  • 12.9.4 KEY DEVELOPMENTS 131
  • 12.9.5 SWOT ANALYSIS 132
  • 12.9.6 KEY STRATEGIES 132
• 12.10 NORBROOK LABORATORIES 133
  • 12.10.1 COMPANY OVERVIEW 133
  • 12.10.2 FINANCIAL OVERVIEW 133
  • 12.10.3 PRODUCTS/SERVICES OFFERED 133
  • 12.10.4 KEY DEVELOPMENTS 135
  • 12.10.5 SWOT ANALYSIS 135
  • 12.10.6 KEY STRATEGIES 136

13 APPENDIX

• 13.1 REFERENCES 137
• 13.2 RELATED REPORTS 138